291: The plight of the VC, Gilead's latest setback, & more M&A
The Readout Loud
00:00
Gilead's Strategy in Oncology and CAR-T Therapy
This chapter explores Gilead Sciences' attempts to replicate their success in viral infections in the field of oncology, and discusses the potential of CAR-T therapy as their key focus. It also delves into Gilead's manufacturing capabilities and acquisition strategies.
Transcript
Play full episode
